Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

NCT01614886 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

216

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: Active Comparator
DRUG: ENA713

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]